These trials completed more than 12 months ago and should have reported results.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
|Status||Trial ID||Title||Completion date||Category|
|Reported results||2006-003580-31||A Study of the Efficacy of MORAb-003 in Subjects with Platinum-Sensitive Epithelial Ovarian Cancer in First Relapse||2010-02-02||due-trials|
|Reported results||2007-007633-39||A Phase 2 Randomized, Placebo-Controlled, Double-Blind Study Of The Efficacy Of MORAb-009 In Combination With Gemcitabine In Patients With Advanced Pancreatic Cancer||2009-12-16||due-trials|
|Reported results||2008-005448-18||An Open-Label Clinical Trial of MORAb-009 in Combination With Pemetrexed and Cisplatin in Subjects With Mesothelioma||2013-12-31||due-trials|
|Completed, but no date, and reported results Terminated||2008-005449-43||A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of MORAb-003 (farletuzumab) in Combination with Paclitaxel Therapy in Subjects with Platinum-Resistant or Refractory Rel...||bad-data|
|Completed, but no date, and reported results Terminated||2009-015825-36||An Open Label Extension Study of the Efficacy of MORAb-003 in Subjects with Platinum-Sensitive Epithelial Ovarian Cancer in First Relapse||bad-data|
|Listed as ongoing, but also has a completion date and reported results||2010-022229-13||A Randomized, Double-Blind, Placebo-Controlled, Study of the Safety and Efficacy of Farletuzumab in combination with Carboplatin and Paclitaxel or Docetaxel Followed by Pemetrexed in Chemotherapy na...||2013-10-31||bad-data|
|Ongoing||2011-001282-40||A Study of the Efficacy and PK/PD Relationship of Monotherapy MORAb-004 in Subjects with Metastatic Melanoma||not-yet-due|
|Reported results||2012-001399-12||A Study of the Safety and Efficacy of the Combination of Gemcitabine and Docetaxel with MORAb-004 in Metastatic Soft Tissue Sarcoma||2016-02-29||due-trials|
|Listed as ongoing, but also has a completion date||2014-003812-36||A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination with Carboplatin plus Paclitaxel or Carboplatin plus Pegylate...||2020-08-13||bad-data|
|Ongoing, reported early||2014-004489-85||A Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Amatuximab in Combination with Pemetrexed and Cisplatin in Subjects with Unresectable Malignant Pleural Mesothelioma||not-yet-due|